Fundraising Fox

Elegen

San Carlos, US · Founded 2017 · Delaware corporation · 60 employees on LinkedIn · 8 known investors

Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.

BiotechDeep Tech

Founders & leadership

Elegen was founded in 2017 by Matthew Hill.

MHMatthew Hill
Matthew HillinFounderMatthew Hill is an executive officer and director at Elegen, which develops DNA synthesis technology and services, including ENFINIA DNA synthesis at scale for biotech and research applications. He has over 20 years of experience in the life sciences spanning research, product development, and leadership.

Board

PZPeter Zhou
Peter ZhouinBoard MemberGeneral Partner at Triatomic Capital
CMCain McClary
Cain McClaryin𝕏Board directorManaging Partner & Founder at KdT Ventures
JS
Jonathan SheenaBoard director

Investors · 8

ACVC PartnersSilicon Valley
Andreessen HorowitzMenlo Park · $500K – $50M
Raptor GroupMiami Beachvia James J. Pallotta · inferred
Triatomic CapitalPalo Alto · $100K – $1M
AME Cloud VenturesreportedPalo Alto · $1M – $10M
Digitalis VenturesreportedNew York · $100K – $10M
In-Q-TelreportedTysons · $100K – $2.5M
KdT Venturesreported · 3 sourcesAustin · $500K – $3M

Reported raises · per SEC filings

Form D private placements

$33M disclosed across 1 round · 2024

▶$33MraisedMay 2024 · 28 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew HillExecutive Officer, Director
  • Peter ZhouDirector
  • Jonathan SheenaDirector
  • Cain McClaryDirector
Offering amount
$36M
Amount sold
$33M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Origene32 shared keywordsOriGene supplies research reagents including primary antibodies for flow cytometry, transfection kits (EZ-LNP and ProteanFect), RNAi gene silencing tools, and control solutions for life science laboratories. Its products serve researchers in molecular and cell biology.

Companies competing with Elegen for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Elegen Raises the Bar for Synthetic DNA by Lowering Prices Across Its ENFINIA™ Portfoliobusinesswire.com · Jan 2026Revolutionizing Synthetic Biology: ELEGEN Secures $35M in Series B Funding | SignalBasetrysignalbase.com · Jul 2024Elegen Raises $35M in Series B Funding to Advance DNA Synthesis - Woodgate Computerswoodgatecomputers.com · May 2024Elegen Raises $35M in Series B Financing Round | GenomeWebgenomeweb.com · May 2024Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturingbusinesswire.com · May 2024

Frequently asked questions

What does Elegen do?
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
Who founded Elegen?
Elegen was founded by Matthew Hill in 2017.
Who are Elegen's investors?
Elegen's investors include ACVC Partners, Andreessen Horowitz, Raptor Group, Triatomic Capital, AME Cloud Ventures, Digitalis Ventures, In-Q-Tel, KdT Ventures.
How much funding has Elegen raised?
Elegen has disclosed $33M raised across 1 round.
Where is Elegen headquartered?
Elegen is headquartered in San Carlos, US.